response, as defined in section 10.0, then additional boosters will be given up to 
one year in duration or until progression of disease. Six patients will receive a 
low dose vaccine and the additional six will receive higher dose (see section 7.1). 
3.0 CRITERIA FOR PATIENT ELIGIBILITY 
Patients must fulfill the following criteria to be eligible for study admission: 
3.1 Patients with histologic confirmation of metastatic malignant melanoma at 
MSKCC. 
3.2 Stage IV disease that is not curable by surgical resection. 
3.3 Patients must have measurable or evaluable disease. 
3.4 Kamofsky performance status greater than or equal to 70% and life 
expectancy greater than 4 months. 
3.5 Adequate hematologic function with WBC _> 3000/mm 3 , absolute 
lymphocyte count > 1000/mm 3 , hemoglobin _> 9, and platelets J> 
100,000/mm 3 . 
3.6 Adequate renal and hepatic function (serum creatinine <_ 2.5 mg/dl and 
bilirubin _< 1.7 mg/dl). 
3.7 At least 4 weeks since any prior radiation therapy, immunotherapy, or 
chemotherapy (6 weeks for nitrosoureas), and full recovery from such 
treatment. 
3.8 The ability to give written informed consent. 
3.9 Age _> 18 years. 
3.10 No history of other concurrent malignancies except basal cell carcinoma, 
squamous cell carcinoma of the skin, or carcinoma-in-situ of the cervix. 
3.11 No systemic steroids for at least one week prior to treatment. 
3.12 No intracranial or multiple hepatic metastases. 
3.13 Patients must be HLA-A2 positive. 
[896] 
Recombinant DNA Research, Volume 15 
